Intellia Therapeutics Inc (NTLA)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES

40 ERIE STREET CAMBRIDGE, MA 02139

Intellia Therapeutics, Inc. operates as a biotechnology company. The Company focuses on the research and clinical development of gene editing therapies for patients with genetically-based diseases.

Data based on most recent fiscal year report
Market Cap702.406 Million Shares Outstanding48.88 Million Avg Volume765.021 Thousand
1-Yr BETA vs S&P TR2.352 Current Ratio8.01 Quick Ratio8.01
View SEC Filings from NTLA instead.

View recent insider trading info

Funds Holding NTLA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NTLA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FORMELA JEAN FRANCOIS

  • Director
0 2020-01-02 1

LEONARD JOHN M.

  • Director
8,252 2019-12-20 0

COHEN FRED E

  • Director
0 2019-11-08 2

TLS BETA PTE. LTD.

TEMASEK LIFE SCIENCES PRIVATE LTD

FULLERTON MANAGEMENT PTE LTD

TEMASEK HOLDINGS (PRIVATE) LTD

  • 10% Owner
0 2019-10-10 0

GORDON CARL L

  • Director
  • 10% Owner
0 2019-09-12 0

SCHIERMEIER ANDREW EVP, CHIEF OPERATING OFFICER

  • Officer
0 2019-08-01 2

BAKER BROS. ADVISORS LP

BAKER BROS. ADVISORS (GP) LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
4,685,574 2019-07-01 0

SLAOUI MONCEF

  • Director
0 2019-06-27 0

DORSA CAROLINE

  • Director
20,207 2019-06-19 1

KARSEN PERRY A

  • Director
0 2019-06-13 1

SEPP-LORENZINO LAURA EVP, CHIEF SCIENTIFIC OFFICER

  • Officer
0 2019-06-03 2

VERWIEL FRANK

  • Director
0 2019-05-21 1

GOODMAN JESSE

  • Director
0 2019-05-21 1

NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

NOVARTIS AG

  • 10% Owner
4,352,295 2018-12-31 0

RIVERA JOSE E EVP, GENERAL COUNSEL

  • Officer
0 2018-12-18 0

GODDARD GLENN EVP, CHIEF FINANCIAL OFFICER

  • Officer
0 2018-12-18 0

HAYES JOHN T. SEE REMARKS

  • Officer
0 2018-08-03 0

ATLAS VENTURE FUND IX, L.P.

ATLAS VENTURE ASSOCIATES IX, L.P.

ATLAS VENTURE ASSOCIATES IX, LLC

  • 10% Owner
4,645,453 2018-04-23 0

BELL GRAEME EVP, CHIEF FINANCIAL OFFICER

  • Officer
21,400 2018-03-28 0

CARIBOU BIOSCIENCES, INC.

No longer subject to file 2018-01-29 0

BERMINGHAM NESSAN PRESIDENT & CEO

  • Officer
  • Director
0 2017-12-12 0

ATLAS VENTURE ASSOCIATES IX, L.P.

ATLAS VENTURE ASSOCIATES IX, LLC

  • 10% Owner
3,729,788 2017-03-09 0

MORRISSEY DAVID V SVP, PLATFORM & DELIVERY TECH

  • Officer
0 2017-01-06 0

BARNES THOMAS M. SVP, R&D EXTELLIA

  • Officer
0 2017-01-06 0

HEIFNER NICOLE SVP, ACCOUNTING

  • Officer
0 2017-01-06 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP V LLC

ORBIMED GLOBAL HEALTHCARE GP LLC

ISALY SAMUEL D

  • Director
2,662,180 2016-05-11 0

CARIBOU THERAPEUTICS HOLDCO, LLC

CARIBOU BIOSCIENCES, INC.

  • 10% Owner
5,593,846 2016-05-11 0

HAURWITZ RACHEL E.

  • Director
  • 10% Owner
5,593,846 2016-05-11 0

FORESITE CAPITAL MANAGEMENT III, LLC

FORESITE CAPITAL FUND III, L.P.

TANANBAUM JAMES B.

  • 10% Owner
0 2016-05-05 0

SRIVASTAVA SAPNA CHIEF FINANCIAL & STATEGY OFFR

  • Officer
159,031 2016-05-05 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions
Click here to report any possible errors with this stock listing.

Elevate your investments